account_id none on file
legal_name CytoMed Therapeutics Ltd
ticker GDTC
cik 1873093
domain cytomed.sg
linkedin_company_url https://www.linkedin.com/company/cytomed-therapeutics-limited/?viewAsMember=true
entry_point_account_id none on file
name CytoMed Therapeutics Limited
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 6 family 0
why_nownone on file
callsnone on file
filings
facilities in Malaysia for cost efficiency. We intend to focus on developing the following technology platforms centered on allogeneic immune cell-based cancer therapy and stem cell-based therapy for degenerative diseases: 1.
filing / Mar 31, 2026 / receipt
Executive Directors CHOO Chee Kong | 68 | Director and Chairman
filing / Mar 31, 2026 / receipt
Dr. ZENG Jieming | 53 | Director and Chief Scientific and Medical Officer
filing / Mar 31, 2026 / receipt
CHOO Chee Kong | 68 | Chairman and Director
filing / Mar 31, 2026 / receipt
Dr. ZENG Jieming | 53 | Chief Scientific and Medical Officer and Director
filing / Mar 31, 2026 / receipt
Dr. Lucas LUK Tien Wee | 42 | Chief Clinical Officer
filing / Mar 31, 2026 / receipt
GOH Yvonne | 37 | Chief Financial Officer
filing / Mar 31, 2026 / receipt
TAN Yoong Ying | 38 | Chief Corporate Officer
filing / Mar 31, 2026 / receipt
executives
| CHOO Chee Kong | Chairman and Director | - | receipt |
| Dr. Lucas LUK Tien Wee | Chief Clinical Officer | - | receipt |
| Dr. ZENG Jieming | Chief Scientific and Medical Officer and Director | - | receipt |
| Executive Directors CHOO Chee Kong | Director and Chairman | - | receipt |
| GOH Yvonne | Chief Financial Officer | - | receipt |
| TAN Yoong Ying | Chief Corporate Officer | - | receipt |
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug cytomed-therapeutics-limited
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$